Dr. Merrîcc Edgar-Hughes, PhD has over 20 years’ experience in Medical Device and Medicine Quality and Regulatory Affairs. Merrîcc has held several senior leadership positions including Head of Pharmaceutical and Consumer Health (ANZ) at Bayer, Head of Regulatory Affairs and Pharmacovigilance (ANZ) at Eli Lily, Head of Biomedical and Regulatory Affairs (ANZ) at Genzyme and Regulatory Affairs Manager (Global) at Nanosonics. Merrîcc has extensive experience in product development, launch excellence and lifecycle management across many therapeutics’ areas and product categories.

Dr. Ron Weinberger is the Former Exec Director and CEO of Nanosonics' (ASX:NAN), an $2bn market cap healthcare company. He has over 20-years’ experience developing and commercialising medical devices. During his time at Nanosonics, Dr. Weinberger co-developed the company’s platform technology, launched their breakthrough product ‘Trophon’ globally and created a North American sales team to work alongside GE healthcare. He was instrumental in transforming Nanosonics from a research and development company to one of Australia’s leading medical device commercialisation success stories.

Konstanty received the dual B.Eng./B.Sc. (Hons.) degree and the Ph.D. degree in wireless communications from the University of Queensland, Brisbane, QLD, Australia, in 2003 and 2008, respectively. He was a Research Engineer with National ICT Australia, Melbourne, VIC, Australia, prior to joining the School of Information Technology and Electrical Engineering at the University of Queensland in 2009, where he is currently a Research Fellow. His research interests include near-field and passive radar systems, multiple element antenna systems, and wireless communications. He was a recipient of the Early CAREER Researcher Award at the 2011 Australian Communication Theory Workshop and the Highly Commended Presentation Award at the 2005 Australian Symposium on Antennas.

Emma has diverse global corporate advisory, capital markets and corporate governance experience having held roles in accounting and debt and equity capital markets in Australia and the United Kingdom. Emma is a Member of the Australian Institute of Chartered Accountants, a Fellow of the Financial Services Institute of Australasia and a Certificated Member of the Governance Institute of Australia.

Ms Khandan has over 17 years’ experience in the development of regulated products in numerous industries including automotive and medical devices. Before EMVision, she was Program Manager at Nanosonics (ASX:NAN), reporting directly to the CTO, where she led a large multi-disciplined team of engineers and scientists across the business. During her 9-year tenure at Nanosonics, Forough successfully planned and executed highly complex new technology and product development programs and was key in leading activities required to define, develop, and deliver Nanosonics' new products including the second generation of trophon device from prototype to after-market release.

Robert has over 25 years’ experience in medical device product design and commercialisation. As CEO of Tiller Design, Robert and his team, in collaboration with Nanosonics R&D team, developed the Trophon EPR device. That device underpinned Nanosonics success spring boarding the company to a market capitalisation of over $2 billion.

Co-inventor of EMVision’s underlying technology, Professor Stuart Crozier is also the former Director of Biomedical Engineering at the University of Queensland. Professor Crozier’s advancements in MRI technology have been used in billions of scans around the world and are now central to 65% of all MRI machines manufactured since 1997. Professor Crozier brings a wealth of experience in developing and commercialising medical imaging systems.

Scott is the co-founder of EMVision Medical Devices Ltd. Scott has held several senior sales positions, including Head of Client Sales at Quantcast, a US-based technology company, prior to founding Kirkland Capital, targeting emerging technologies. Scott oversees EMVision's corporate affairs, commercial strategy and business development efforts. Scott is also charged with optimising the company’s capital requirements, including further non-dilutive financing and grants. Scott is a member of the Australian Institute of Company Directors.

Dr. Walsham is a senior staff specialist at the Princess Alexandra Hospital in Brisbane. In his role as director of research within the ICU he is the site principal investigator in a wide range of research activities including large multicentre trials as well as industry sponsored trials. Dr Walsham completed his basic medical degree at Manchester University in the UK before moving to Australia where he completed his Intensive Care training in Queensland.

Dr. Mitchell is a practising Interventional Neuroradiologist (CCINR accredited) who provides care, management and treatment of neurovascular disease, including stroke, in Brisbane. Dr Mitchell performs Endovascular Clot Retrieval in acute stroke that requires mechanical clot retrieval at the Royal Brisbane and Women's Hospital and other major Brisbane Hospitals. Dr Mitchell is also a Senior Lecturer at the University of Queensland. In addition to his work in more recent interventional Stroke care, Dr Mitchell has close to 30 years’ experience in the management of brain and spine vascular disease including aneurysms and vascular malformations.

Professor O’Sullivan is a neuroscientist and neurologist in Brisbane. He is a professor and member of the Executive of the UQ Centre for Clinical Research and a Staff Specialist in Neurology at the Royal Brisbane and Women's Hospital. Here he participates in the hyperacute stroke and clot retrieval service, providing acute care to patients in Brisbane and much of central and northern Queensland. Prof O’Sullivan’s research focus is translational in nature, promoting restoration of brain function after stroke. His work utilises advanced imaging techniques and focuses on memory function, cognitive control, ageing and early cognitive decline and dementia. He co-chairs the Cognition Group of the International Stroke Recovery and Rehabilitation Roundtable. Professor O’Sullivan trained as an undergraduate in Cambridge, did specialist training in London, was a Medical Research Council Clinician Scientist Fellow from 2008- 2012 and then academic lead for stroke at King’s Health Partners in London.

Dr. Cook is a senior critical care specialist and anaesthetist at Brisbane’s PA Hospital’s Intensive Care Unit. His PhD in 2003 from the University of Queensland (UQ) Information Technology and Electrical Engineering school, developed prediction models using machine learning and sequential statistics. He is Associate Professor with UQ Faculty of Medicine and Adjunct Professor with Queensland University of Technology Science and Engineering Faculty. Dr Cook has published across a wide range of topics and disciplines including toxicology and pharmacology, biochemistry, statistics and modelling, epidemiology, process improvement and heath economics, and has a research interest in integration of information from disparate sources and the measurement of “quality of knowledge.”

Alliance Fellow, Angela is Australia’s first Indigenous neurologist based at the Melbourne Brain Centre at Royal Melbourne Hospital, where she also works on the Melbourne Mobile Stroke Unit. Angela will be a key clinical expert for our aeromedical plans and is co-chair of our Aboriginal and Torres Strait Islander Leadership Council. Her doctoral research is focussed on stroke in Aboriginal and Torres Strait Islander Australians. Angela is an “ex-officio” member of EMVision’s Clinical Advisory Board.

Stephen is a professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital and a Past-President of the World Stroke Organization. He co-chairs the Melbourne Mobile Stroke Unit program. His research is focussed on acute therapy for both ischemic stroke and intracerebral haemorrhage, particularly the use of advanced imaging in selection of therapy. He is the co-lead of the Frontiers MRFF grant on Prehospital Stroke Care. Stephen is an “ex-officio” member of EMVision’s Clinical Advisory Board.

Geoffrey is a professor of Neurology at The University of Melbourne and former Director of The Florey Institute of Neuroscience and Mental Health. His research interest is clinical stroke management.  He was co-founder, with Professor Stephen Davis, of the Australian Stroke Trials Network.  He is the co-chair of the EXTEND group of trials, including the recently published EXTEND IA trial of thrombectomy in acute ischaemic stroke.  He was Editor-in-Chief of the International Journal of Stroke and is Past President of the World Stroke Organisation. Geoffrey is an “ex-officio” member of EMVision’s Clinical Advisory Board.

Professor Crozier is co-inventor of EMVision’s underlying technology and the Director of Biomedical Engineering at the University of Queensland. Professor Crozier’s advancements in MRI technology, having licenced them to GE Healthcare and Siemens Healthineers, are now central to more than 65% of all MRI machines manufactured since 1997 and have been used in billions of scans around the world. Professor Crozier brings a wealth of experience in developing new medical imaging systems and applications that have had a significant global impact.